BioNexus Gene Lab is a molecular diagnostics company focused on the application of functional genomics. Co.'s focus is on developing and marketing non-invasive blood tests for early detection of diseases. Co.'s non-invasive blood tests analyze changes in ribonucleic acid to detect the risk potentiality of various diseases. These diseases include cancers (nasopharyngeal, lung, liver, stomach, breast, cervical, prostate and colon), bowel diseases (colitis and Crohn) and osteoarthritis. This blood based genomic biomarker approach is based on the scientific observation that circulating blood reflects, in a detectable way, what is occurring throughout the body. The BGLC average annual return since 2021 is shown above.
The Average Annual Return on the BGLC average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether BGLC average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the BGLC average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|